Robust TMTT Growth to Drive Edwards Lifesciences' Q2 Earnings
In the last reported quarter, the company's adjusted earnings per share of 64 cents beat the Zacks Consensus Estimate by 6.67%. Its earnings beat estimates in two of the trailing four quarters and matched on the other two occasions, the average surprise being 3.49%.
Q2 Estimates
The Zacks Consensus Estimate for revenues is pegged at $1.49 billion, suggesting an 8.9% decline from the year-ago reported figure.
The Zacks Consensus Estimate for net earnings of 62 cents per share indicates an 11.4% decline from the year-ago reported figure.
Estimate Revision Trend Ahead of Edwards' Q2 Earnings
Estimates for earnings have remained unchanged at 62 cents per share in the past 60 days.
Here's a brief overview of the company's progress ahead of this announcement.
Factors at Play
In the second quarter of 2025, the Transcatheter Aortic Valve Replacement ('TAVR') arm is likely to have delivered a strong performance in the United States, thanks to its market-leading SAPIEN 3 Ultra RESILIA platform. The continued expansion of SAPIEN3 Ultra RESILIA in Europe is expected to have supported the international performance. The platform has demonstrated remarkable patient outcomes, and the momentum is expected to have continued with more centers adopting it. Although we expect the company to have endured a weak procedure growth environment and competitive pressure in Japan, it remained dedicated to addressing significant undertreatment of aortic stenosis among the country's substantial elderly population.
On its previous earnings call, Edwards stated that it experienced a few instances of regional variability despite holding a strong competitive position and stable global pricing. The trend is likely to have continued in the second quarter, restricting the segment's full potential. Our model assumes TAVR sales to be $1.09 billion, implying a 5.2% year-over-year increase.
In the Transcatheter Mitral and Tricuspid Therapies ('TMTT') segment, strength in the portfolio of repair and replacement technologies for both Mitral and Tricuspid valves is likely to have supported Edwards' performance in second-quarter 2025. The PASCAL repair system is expected to have gained traction in the United States, Europe and globally, thanks to its differentiated features, leading to increased adoption of the technology at both existing and new centers.
Additionally, the commercial launch of the EVOQUE tricuspid replacement system might have continued to progress in the United States and Europe. As of March, it gained Medicare coverage under the finalized NCD for transcatheter tricuspid valve replacement, expanding access.
Edwards Lifesciences Corporation Price and EPS Surprise
Edwards Lifesciences Corporation price-eps-surprise | Edwards Lifesciences Corporation Quote
Edwards has raised its 2025 sales guidance for this segment to $530-$550 million (earlier $500 million), and we expect the company to have progressed meaningfully in the to-be-reported quarter. Our model estimates the TMTT business to report revenues of $130.4 million, implying a 57.1% improvement from the year-ago period's level.
Lastly, Edwards' Surgical Structural Heart might have delivered a strong performance in the to-be-reported quarter, driven by global adoption of its premium RESILIA portfolio, including MITRIS, INSPIRIS and KONECT. The company likely saw positive procedural growth globally for the many patients best treated surgically, including complex and concomitant procedures. Furthermore, MITRIS' launch in China with positive surgeon feedback might have contributed to the second-quarter top line.
Our model estimates the segment's revenues to be $263.1 million, suggesting a modest 6.2% rise from the year-ago quarter's reported figure.
Earnings Whispers for Edwards
Per our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates, which is not the case here, as you can see below:
Earnings ESP: Edwards has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here.
Top MedTech Picks
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this reporting cycle:
CVS Health CVS has an Earnings ESP of +2.06% and a Zacks Rank #1 at present. The company is slated to release second-quarter 2025 results on July 31. You can see the complete list of today's Zacks #1 Rank stocks here.
CVS' earnings surpassed estimates in each of the trailing four quarters, the average surprise being 18.08%. The Zacks Consensus Estimate for second-quarter EPS implies a year-over-year decline of 19.7%.
Cencora COR has an Earnings ESP of +1.49% and a Zacks Rank #2 at present. The company is slated to release third-quarter fiscal 2025 results on Aug. 6.
The company's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.00%. The Zacks Consensus Estimate for fiscal third-quarter EPS implies a year-over-year increase of 13.2%.
Cardinal Health CAH has an Earnings ESP of +0.68% and a Zacks Rank #2 at present. The company is expected to release fiscal fourth-quarter 2025 results on Aug. 12.
CAH's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 10.30%. The Zacks Consensus Estimate for fiscal fourth-quarter EPS suggests a year-over-year improvement of 1.3%.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Cardinal Health, Inc. (CAH): Free Stock Analysis Report
Edwards Lifesciences Corporation (EW): Free Stock Analysis Report
CVS Health Corporation (CVS): Free Stock Analysis Report
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
6 minutes ago
- CBC
Detroit Three lobbying group criticizes deal favouring Japanese imports
Social Sharing Shares of General Motors, Ford Motor, and Stellantis some of the biggest automakers in the U.S., rallied on Wednesday after news of a trade deal that will reduce tariffs on imported Japanese cars, as investors saw it as a sign of more deals to come. But the companies are not celebrating. Automakers importing vehicles into the U.S. from Japan now face a 15 per cent levy, according to terms of the deal outlined on Tuesday by U.S. President Donald Trump, down from 27.5 per cent. GM shares rallied 9 per cent and Stellantis rose 12 per cent, as market watchers said they anticipated further agreements could reduce other trade barriers that have hurt the companies' profits. Ford shares rose about 2 per cent. The automaker is less exposed to tariffs because it produces more of its U.S.-sold vehicles domestically. On Wednesday, the European Union and United States were nearing a trade deal that would also set a 15 per cent tariff on European imports. GM, Ford and Stellantis have been paying up to 25 per cent on vehicles imported from Mexico or Canada, depending on how much U.S. content is in the vehicles. The companies are concerned they could soon be paying higher tariffs on vehicles assembled in Mexico or Canada than on vehicles with significantly less U.S. content made in Japan or the United Kingdom. WATCH | U.S., Japan reach trade deal with 15% tariffs on imported Japanese goods: U.S., Japan reach trade deal with 15% tariffs on imported Japanese goods 22 hours ago Some lobbyists also expressed alarm that if South Korea strikes a similar deal with the U.S., it could become a low-cost market to assemble cars and trucks. "They could be the new Mexico," one lobbyist told Reuters. The American Automotive Policy Council, which represents the Detroit Three, criticized the deal, saying it creates an easier path for Japanese imports than for some cars built in North America. Even before Tuesday's deal, Detroit automotive executives raised concerns that Trump's trade policy could end up giving an edge to foreign automakers who do not invest as heavily in U.S. manufacturing. "This is a bonanza for our import competitors," Ford CEO Jim Farley said in February, when Trump initially proposed levies on Mexico and Canada, but not on major automotive centers such as South Korea. The United Auto Workers union, which represents workers at the Detroit Three automakers, said it was "deeply angered" by the deal. "What we've seen so far makes one thing clear: American workers are once again being left behind," the union said in a statement on Wednesday evening. Th Japan trade announcement came the same day General Motors said tariff costs knocked $1.1 billion USD from its bottom line, hurt by a battery of levies including 25 per cent taxes on imports from Canada and Mexico, and 50 per cent on steel and aluminum imports. Industry consultant and former GM executive Warren Browne said the Japan deal "put all vehicles produced in Mexico and Canada by the Detroit Three at a disadvantage," because they face higher levies than Toyota vehicles shipped in from Japan, for example. That could allow the foreign brands to undercut U.S. car companies on price. The Windsor Assembly Plant could be in trouble if tariffs don't disappear, as company posts losses: Auto expert 3 days ago Toyota, Subaru and Mazda are among the most reliant companies on Japan-produced vehicles for their U.S. sales, and stand to benefit most from the lower tariffs, according to business-analytics firm GlobalData. Toyota imported roughly 500,000 vehicles from Japan last year. Japanese automotive stocks soared after the trade deal announcement. Autos Drive America, which represents those Japanese automakers along with other foreign car companies operating in the United States, on Wednesday praised the trade deal, saying it would lead to further factory investment in the U.S. Treasury Secretary Scott Bessent warned, however, that non-compliance by Japan on the trade agreement would result in a return to the higher tariff rate. "We'll evaluate (compliance) every quarter and if the president's unhappy then we'll boomerang it back to the 25 per cent tariff rate, both on cars and the rest of their products," he said in an interview on Fox News.
CTV News
7 minutes ago
- CTV News
Loblaw's Q2 profit up from a year ago amid higher customer traffic
A customer looks for produce at a grocery store in Ottawa, on Wednesday, April 2, 2025. THE CANADIAN PRESS/Justin Tang BRAMPTON — Loblaw Companies Ltd. reported its second-quarter profit rose compared with a year ago as the company says customer traffic, basket size and item count all increased year-over-year. The parent company of Loblaws and Shoppers Drug Mart says its net earnings available to common shareholders amounted to $714 million or $2.37 per diluted share for the quarter ended June 14. The result was up from a profit of $457 million or $1.48 per diluted share in the second quarter of 2024. On an adjusted basis, Loblaw says it earned $2.40 per diluted share in its latest quarter, up from an adjusted profit of $2.15 per diluted share a year earlier. Revenue for the quarter totalled $14.7 billion, up from $13.9 billion, as food retail same-store sales rose by 3.5 per cent. Drug retail same-store sales rose 4.1 per cent, with pharmacy and health care services same-store sales up 6.2 per cent, and front store same-store sales increasing 1.7 per cent. This report by The Canadian Press was first published July 24, 2025.
Globe and Mail
37 minutes ago
- Globe and Mail
D-Wave Quantum to Report Second Quarter Fiscal Year 2025 Financial Results on August 7, 2025
D-Wave Quantum Inc. (NYSE: QBTS) ('D-Wave'), a leader in quantum computing systems, software, and services, today announced it will release its financial results for the second quarter of fiscal year 2025 ended June 30, 2025 on Thursday, August 7 before market open. The press release will be available on the D-Wave Investor Relations website: In conjunction with this announcement, D-Wave will host a conference call on Thursday, August 7, 2025, at 8:00 a.m. (Eastern Time), to discuss the Company's financial results and business outlook. The live dial-in number is 1-800-717-1738 (domestic) or 1-646-307-1865 (international). Participants can use those dial-in numbers or can click this link for instant telephone access to the event. The link will be made active 15 minutes prior to the call's scheduled start time. An on-demand webcast will be available on the D-Wave Investor Relations website after the call. Participating in the call will be Chief Executive Officer Dr. Alan Baratz and Chief Financial Officer John Markovich. About D-Wave Quantum Inc. D-Wave is a leader in the development and delivery of quantum computing systems, software, and services. We are the world's first commercial supplier of quantum computers, and the only company building both annealing and gate-model quantum computers. Our mission is to help customers realize the value of quantum, today. Our quantum computers — the world's largest — feature QPUs with sub-second response times and can be deployed on-premises or accessed through our quantum cloud service, which offers 99.9% availability and uptime. More than 100 organizations trust D-Wave with their toughest computational challenges. With over 200 million problems submitted to our quantum systems to date, our customers apply our technology to address use cases spanning optimization, artificial intelligence, research and more. Learn more about realizing the value of quantum computing today and how we're shaping the quantum-driven industrial and societal advancements of tomorrow: Forward-Looking Statements Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading 'Risk Factors' discussed under the caption 'Item 1A. Risk Factors' in Part I of our most recent Annual Report on Form 10-K or any updates discussed under the caption 'Item 1A. Risk Factors' in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.
